Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Robert Doebele, MD
Advertisement
Articles by Robert Doebele, MD
Advertisement
Latest Updated Articles
Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 InhibitorPublished: June 18th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
3
Collagen Implant May Improve Local Control of Metastatic Brain Tumors
4
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
5
